Cellectar Biosciences Inc’s recent filing unveils that its Chief Operating Officer Longcor Jarrod acquired Company’s shares for reported $8400.0 on Jan 10 ’25. In the deal valued at $0.28 per share,30,000 shares were bought. As a result of this transaction, Longcor Jarrod now holds 83,141 shares worth roughly $20785.25.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. ROTH Capital started covering the stock on September 13, 2019. It rated CLRB as “a Buy”.
Price Performance Review of CLRB
On Friday, Cellectar Biosciences Inc [NASDAQ:CLRB] saw its stock fall -3.43% to $0.25. Over the last five days, the stock has lost -0.97%. Cellectar Biosciences Inc shares have fallen nearly -18.06% since the year began. Nevertheless, the stocks have fallen -92.30% over the past one year. While a 52-week high of $3.45 was reached on 03/20/25, a 52-week low of $0.22 was recorded on 01/15/25. SMA at 50 days reached $0.2976, while 200 days put it at $1.0725.
Levels Of Support And Resistance For CLRB Stock
The 24-hour chart illustrates a support level at 0.2384, which if violated will result in even more drops to 0.2318. On the upside, there is a resistance level at 0.2547. A further resistance level may holdings at 0.2644. The Relative Strength Index (RSI) on the 14-day chart is 41.60, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0086, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.72%. Stochastics %K at 21.25% indicates the stock is a holding.
The most recent change occurred on December 21, 2016 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $2.70 price target.
